TY - JOUR
T1 - Clinical characteristics and outcome of bone-only metastasis in inflammatory and noninflammatory breast cancers
AU - Kai, Megumi
AU - Kogawa, Takahiro
AU - Liu, Diane D.
AU - Fouad, Tamer M.
AU - Kai, Kazuharu
AU - Niikura, Naoki
AU - Hsu, Limin
AU - Willey, Jie S.
AU - Theriault, Richard L.
AU - Valero, Vicente
AU - Ueno, Naoto T.
N1 - Publisher Copyright:
© 2015 Elsevier Inc. All rights reserved.
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Background Inflammatory breast cancer is a rare and aggressive presentation of breast cancer. Bone is a common metastatic site in breast cancer, and bone-only metastatic disease is clinically considered to have a better prognosis than visceral metastasis. However, bone-only metastasis in IBC (bone-only IBC) has not been compared with bone-only metastasis in non-IBC (bone-only non-IBC) in terms of clinical features and outcome. Because of the intrinsically aggressive nature of IBC, we hypothesized that bone-only IBC has a poorer prognosis than does bone-only non-IBC.Patients and Methods We retrospectively identified patients with stage III primary diagnosed breast cancer who, between January 1997 and December 2012, had a first recurrence located only in the bone. Among the 197 patients that we defined as a study cohort, 50 patients had IBC and 147 patients had non-IBC. Progression-free survival (PFS) and overall survival (OS) from the date of recurrence were estimated using the Kaplan-Meier method, and patient characteristic groups were compared using the log-rank test.Results OS did not differ significantly between the 2 groups (P =.2467), but a shorter PFS was seen in patients with bone-only IBC than in patients with bone-only non-IBC (P =.0357). Among patients with estrogen receptor (ER)-positive disease, a much shorter PFS was seen in bone-only IBC than in bone-only non-IBC (P =.0159).Conclusion Bone-only IBC has a poorer prognosis than does bone-only non-IBC, particularly in those with ER-positive tumors. We might need to consider more aggressive intervention (eg, chemotherapy) for IBC patients with ER-positive bone-only metastatic disease.
AB - Background Inflammatory breast cancer is a rare and aggressive presentation of breast cancer. Bone is a common metastatic site in breast cancer, and bone-only metastatic disease is clinically considered to have a better prognosis than visceral metastasis. However, bone-only metastasis in IBC (bone-only IBC) has not been compared with bone-only metastasis in non-IBC (bone-only non-IBC) in terms of clinical features and outcome. Because of the intrinsically aggressive nature of IBC, we hypothesized that bone-only IBC has a poorer prognosis than does bone-only non-IBC.Patients and Methods We retrospectively identified patients with stage III primary diagnosed breast cancer who, between January 1997 and December 2012, had a first recurrence located only in the bone. Among the 197 patients that we defined as a study cohort, 50 patients had IBC and 147 patients had non-IBC. Progression-free survival (PFS) and overall survival (OS) from the date of recurrence were estimated using the Kaplan-Meier method, and patient characteristic groups were compared using the log-rank test.Results OS did not differ significantly between the 2 groups (P =.2467), but a shorter PFS was seen in patients with bone-only IBC than in patients with bone-only non-IBC (P =.0357). Among patients with estrogen receptor (ER)-positive disease, a much shorter PFS was seen in bone-only IBC than in bone-only non-IBC (P =.0159).Conclusion Bone-only IBC has a poorer prognosis than does bone-only non-IBC, particularly in those with ER-positive tumors. We might need to consider more aggressive intervention (eg, chemotherapy) for IBC patients with ER-positive bone-only metastatic disease.
KW - Advanced breast cancer
KW - Bone metastasis
KW - Hormone receptor positivity
KW - Overall survival
KW - Progression-free survival
UR - http://www.scopus.com/inward/record.url?scp=84920275306&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84920275306&partnerID=8YFLogxK
U2 - 10.1016/j.clbc.2014.06.007
DO - 10.1016/j.clbc.2014.06.007
M3 - Article
C2 - 25258308
AN - SCOPUS:84920275306
SN - 1526-8209
VL - 15
SP - 37
EP - 42
JO - Clinical breast cancer
JF - Clinical breast cancer
IS - 1
ER -